Effects of mobilized peripheral blood stem cells on treatment of primary lower extremity lymphedema

Ehyaeeghodraty, Vida; Molavi, Behnam; Nikbakht, Mohsen; Mohammadi, Abolfazl; Mohammadi, Saeed; Ehyaeeghodraty, Navid; Fallahi, Babak; Mousavi, Seyed Asadollah; Vaezi, Mohammad; Sefidbakht, Sepideh

doi:10.1016/j.jvsv.2019.10.019

Cited by 4 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…MSCs exhibit immunomodulatory effects [ 106 ], and Jørgensen et al suggested that ADRC transplantation could alleviate the incidence of cellulitis in patients with breast cancer-related lymphedema during a 4-year follow-up period [ 101 ]. Additionally, bone marrow-derived mononuclear cells and peripheral blood hematopoietic stem cells could decrease edema volume in primary lower limb lymphedema without serious adverse events [ 102 , 103 ]. Although the molecular mechanism underlying their therapeutic efficacy is unclear at present, cell-based therapy is attractive to establish new therapeutic strategies for primary and secondary lymphedema.…”

Section: Discussionmentioning

confidence: 99%

“…Somatic stem cell-based therapy for lymphedema in humans has been reported by five research groups ( Table 2 ). The therapeutic efficacy of autologous transplantation was evaluated with bone marrow-derived MSCs or ADRCs for patients with breast cancer-related lymphedema [ 97 , 98 , 99 , 100 , 101 ] and with bone marrow-derived mononuclear cells and peripheral blood hematopoietic stem cells for patients with primary lower limb lymphedema [ 102 , 103 ]. The volume of the edematous limb decreased with cell-based therapy in four groups, while subjective symptoms including heaviness, tension, pain, sensitivity, and mobility of the affected limb and total QOL scores improved in all groups; these effects continued throughout the 4-year follow-up [ 101 ].…”

Section: Cell-based Therapy For Lymphedemamentioning

confidence: 99%

See 1 more Smart Citation

Emerging Anti-Inflammatory Pharmacotherapy and Cell-Based Therapy for Lymphedema

Ogino

Yokooji

Hayashida

et al. 2022

IJMS

View full text Add to dashboard Cite

Secondary lymphedema is a common complication of lymph node dissection or radiation therapy for cancer treatment. Conventional therapies such as compression sleeve therapy, complete decongestive physiotherapy, and surgical therapies decrease edema; however, they are not curative because they cannot modulate the pathophysiology of lymphedema. Recent advances reveal that the activation and accumulation of CD4+ T cells are key in the development of lymphedema. Based on this pathophysiology, the efficacy of pharmacotherapy (tacrolimus, anti-IL-4/IL-13 antibody, or fingolimod) and cell-based therapy for lymphedema has been demonstrated in animal models and pilot studies. In addition, mesenchymal stem/stromal cells (MSCs) have attracted attention as candidates for cell-based lymphedema therapy because they improve symptoms and decrease edema volume in the long term with no serious adverse effects in pilot studies. Furthermore, MSC transplantation promotes functional lymphatic regeneration and improves the microenvironment in animal models. In this review, we focus on inflammatory cells involved in the pathogenesis of lymphedema and discuss the efficacy and challenges of pharmacotherapy and cell-based therapies for lymphedema.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Cell-based Therapy For Lymphedemamentioning

confidence: 99%

Emerging Anti-Inflammatory Pharmacotherapy and Cell-Based Therapy for Lymphedema

Ogino

Yokooji

Hayashida

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Our data are comparable to a single-center, prospective, non-randomized clinical trial on 10 patients with primary lymphedema, treated with two implants of mobilized PBMNC three weeks apart in terms of volume reduction and improvement of quality of life. 27 Selective filtration device concentrates all populations of limphocytes 4.25 folds, including CD45+ CD3+ T lymphocytes and CD45+ CD19+ B lymphocytes. 21 Despite we did not measure how many Treg are present in our cell concentrate, it could be possible that Treg population concentrated and injected can contribute to revers all of the major hallmarks of lymphedema, such as edema, inflammation, and fibrosis, also promoting lymphatic drainage function as observed in animal model.…”

Section: Discussionmentioning

confidence: 99%

Autologous peripheral blood mononuclear cells for the treatment of lower extremity lymphedema: a preliminary report

Bellisi

2021

Veins and Lymphatics

View full text Add to dashboard Cite

Lymphedema is a chronic devastating disease characterized by the accumulation of fluid in the extremities, tissue progressive changes such as adipose tissue deposition and fibrosis. To restore the functionality and structural integrity of the damaged lymphatic vessels, autologous peripheral blood mononuclear cells (PBMNC) was implanted in 3 sessions, 4 weeks apart, in the affected limb. Each patient was followed for 6 months, monitoring changes in the limb volume. Lymphangiogenesis was evaluated by lymphoscintigraphy, and the monitoring of quality of life. A rapid reduction in the volume of the limbs was observed: 24.5% of volume reduction after the first implant, 18.5% after the second, and 15.3% at 6 months after the third (p<0.05 vs baseline). Lymphoscintigraphy showed a hyper fixation of the tracer along the ipsilateral iliac axis not appreciable at baseline. Implants of autologous PBMNC in patients with primary lower limb lymphedema seems to be a feasible, effective therapy option.

show abstract

“…У одного пациента наблюдалось небольшое увеличение объема нижних конечностей, у трех -без изменений. У 6 пациентов по данным лимфосцинтиграфии зафиксировано усиление лимфооттока, а по результатам биопсии -увеличение количества лимфатических сосудов [39].…”

Section: операции трансплантации клетокunclassified

Current Aspects of Surgical Treatment of Limb Lymphedema

Мышенцев¹,

Katorkin²,

Yarovenko³

2021

Novosti Khirurgii

View full text Add to dashboard Cite

The article provides the literature overview on various current methods of surgical treatment of patients with limb lymphedema. Despite the fact that the basis of the treatment of this pathology is a complex antiedema therapy, the possibilities of conservative therapeutic measures for lymphedema leave much to be desired and cannot often satisfy either patients or clinicians. The use of surgical methods in the treatment of lymphedema has a long history and has gone from various types of resection to reconstructive interventions. The analysis of current literature data has shown that the choice of the volume and method of surgical correction in lymphedema requires a difficult and individual assessment of the pathological changes developing in the disease, which should be identified only with a comprehensive examination of patients. Operations of lymphovenous anastomosis, transplantation of lymph nodes are considered to be the most effective in the prevention or initial stages of lymphedema. With pronounced manifestations of the disease, optimal results are achieved with a reasonable combination of methods improving lymph drainage and operations reducing the excess volume of the affected limb, thereby provided patients with potentially improved functional outcomes and quality of life. The limitations in improvement despite multimodality treatment are consided to be at the level of satisfactory values. The experience of the most lymphedema professionals has to besuggesteda reasonable balance between basic conservative therapy and surgical treatment. Undoubtedly, the results of evaluating these methods will improve the choice of the optimal method for treating patients with limb lymphedema.

show abstract

Effects of mobilized peripheral blood stem cells on treatment of primary lower extremity lymphedema

Cited by 4 publications

References 26 publications

Emerging Anti-Inflammatory Pharmacotherapy and Cell-Based Therapy for Lymphedema

Emerging Anti-Inflammatory Pharmacotherapy and Cell-Based Therapy for Lymphedema

Autologous peripheral blood mononuclear cells for the treatment of lower extremity lymphedema: a preliminary report

Current Aspects of Surgical Treatment of Limb Lymphedema

Contact Info

Product

Resources

About